Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Wilcox

Showing results (441-450 of 454) with videos related to

Pageof 46
Sort By:
Respirology (Carlton, Vic.)|March 4, 2024
Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi-centre registry cohortVeronica Marcoux, Stacey D Lok, Prosanta Mondal, et al.
The European Respiratory Journal|March 1, 2023
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based studyYet H Khor, Max Schulte, Kerri A Johannson, et al.
Respiratory Research|July 9, 2021
Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung diseaseTao Chen, Amy Po Yu Tsai, Seo Am Hur, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Annals of the American Thoracic Society|December 13, 2021
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung DiseaseAlyson W Wong, Yet H Khor, Kathryn Donohoe, et al.
Respiratory Medicine|December 24, 2023
Characteristics and risk factors of interstitial pneumonia with autoimmune featuresSana Vahidy, Jonathan Agyeman, Boyang Zheng, et al.
Obesity (Silver Spring, Md.)|March 7, 2009
Hepatic gene expression in morbidly obese women: implications for disease susceptibilityMarshall B Elam, George S Cowan, Robert J Rooney, et al.
Annals of the American Thoracic Society|September 7, 2023
Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung DiseaseFerhan Saleem, Christopher J Ryerson, Nandini Sarma, et al.
Pageof 46

Showing results (441-450 of 454) with videos related to

Sort By:
Pageof 46
Respirology (Carlton, Vic.)|March 4, 2024
Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi-centre registry cohortVeronica Marcoux, Stacey D Lok, Prosanta Mondal, et al.
The European Respiratory Journal|March 1, 2023
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based studyYet H Khor, Max Schulte, Kerri A Johannson, et al.
Respiratory Research|July 9, 2021
Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung diseaseTao Chen, Amy Po Yu Tsai, Seo Am Hur, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Annals of the American Thoracic Society|December 13, 2021
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung DiseaseAlyson W Wong, Yet H Khor, Kathryn Donohoe, et al.
Respiratory Medicine|December 24, 2023
Characteristics and risk factors of interstitial pneumonia with autoimmune featuresSana Vahidy, Jonathan Agyeman, Boyang Zheng, et al.
Obesity (Silver Spring, Md.)|March 7, 2009
Hepatic gene expression in morbidly obese women: implications for disease susceptibilityMarshall B Elam, George S Cowan, Robert J Rooney, et al.
Annals of the American Thoracic Society|September 7, 2023
Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung DiseaseFerhan Saleem, Christopher J Ryerson, Nandini Sarma, et al.
Pageof 46